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Abstract 
Background 
Depression has repeatedly been linked to subclinical hypothyroidism, and thyroid hormones have 
successfully been used to augment antidepressant treatment. By contrast, the extent of thyroid 
dysfunction in anxiety disorders remains less clear. This is surprising, given that anxiety-related 
symptoms (e.g., nervousness, palpitations, increased perspiration) are highly prevalent in 
hyperthyroidism. The present study was undertaken to synthesise the literature on hypothalamic-
pituitary-thyroid (HPT) axis functioning in anxiety disorders. 
Methods 
The PubMed and PsycINFO databases were systematically searched. Three types of studies were 
included: 1) “comorbidity studies” assessing the prevalence of thyroid disorders in individuals with 
anxiety disorders, 2) “case-control studies” comparing HPT parameters between patients and controls, 
and 3) “correlational studies” assessing self-reported anxiety levels and HPT parameters. Risk of bias 
was assessed via a standardised quality rating. 
Results 
Twenty studies were eligible. Nearly all found the comorbidity between anxiety and thyroid disorders 
was significant. Half of the studies additionally supported the notion of subtle thyroid dysfunction in 
that thyroid-stimulating hormone (TSH) responses to the administration of thyrotropin-releasing 
hormone (TRH) were blunted and an inverse relationship was observed between self-reported anxiety 
levels and TSH. Overall, HPT assessments were well-conducted, but several studies failed to adjust 
their analyses for smoking, BMI, and depression. 
Conclusions 
The findings resonate well with clinical recommendations to routinely screen for thyroid disorders in 
patients with anxiety disorders, and with what is known from basic research about thyroid-brain 
interactions. The results of the risk of bias assessment underscore the importance of further high-
quality experimental and longitudinal epidemiological research. 
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Introduction 
For decades, the hypothalamic-pituitary-thyroid (HPT) axis has been subject to investigation in 
depressive disorders (Fountoulakis et al., 2006). An impetus for this line of research to evolve was that 
patients with overt hypothyroidism exhibit symptoms that overlap with those of major depression 
(Feldman, Shrestha, & Hennessey, 2013). This is not surprising, given the widespread expression of 
thyroid hormone receptors in almost all bodily tissues, including the brain (Bauer, Goetz, Glenn, & 
Whybrow, 2008). Subsequent research has revealed that, conversely, some patients with depressive 
disorders seem to be characterised by subclinical forms of hypothyroidism (Fountoulakis et al., 2006). 
Correspondingly, triiodothyronine (T3) has successfully been used as an augmentation strategy in 
depressed patients who were resistant to standard first line treatments, such as antidepressants 
(Cleare et al., 2015). 
By contrast, far less research has been dedicated to studying HPT functioning in anxiety 
disorders. As with depression, some of the most important anxiety symptoms are mimicked by thyroid 
disorders. For instance, patients with overt hyperthyroidism frequently report anxiety, fatigue, poor 
concentration, and disturbed sleep, all of which constitute core symptoms of generalised anxiety 
disorder (GAD; De Leo, Lee, & Braverman, 2016). In addition, a number of somatic symptoms, such 
as palpitations, shortness of breath, and increased perspiration overlap with what patients with panic 
disorder (PD) experience during panic attacks. The reverse, namely the extent of thyroid dysfunction 
as present in patients with anxiety disorders, however, still remains unclear. Learning more about such 
dysfunction would first mean to obtain an estimate of the presence of (subclinical) thyroid disorders in 
patients with anxiety disorders. Second, it would imply to study subtle alterations in individual HPT 
parameters, i.e., thyrotropin releasing hormone (TRH), thyroid-stimulating hormone (TSH), and the 
thyroid hormones T3, and thyroxine (T4), as has been done in depression. Doing so may shed light on 
the intricate relationship between anxiety and HPT functioning and could help to determine whether 
the above listed anxiety symptoms may emerge as an epiphenomenon of subclinical thyroid 
dysfunction, too. 
In their narrative review of this literature, Simon et al. (2002) found initial support for an 
increased prevalence of thyroid disorders in patients with GAD and PD. However, as noted by the 
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authors, at the time when their review was published, no community or primary care studies were yet 
available, and the authors therefore had to rely on a number of relatively small secondary and tertiary 
care studies, which likely suffered from selection bias. In addition, sufficiently sensitive kits to 
determine TSH were only developed between 1980 and 1990, which may have rendered it impossible 
for some of the included studies to detect subclinical thyroid dysfunction (nine of the 13 included 
studies were published before 1990). Finally, very few data on subtle alterations in the HPT axis were 
available, which may be gained from studies comparing patients’ resting or stimulated thyroid 
parameters with those of healthy controls. 
The present study was therefore undertaken to update and extend this previous review by 
systematically searching and synthesising the literature on HPT functioning in anxiety disorders. Our 
specific aims were threefold: 1) to investigate whether patients with anxiety disorders have an 
increased risk of (subclinical) thyroid disorders, 2) to find out whether the same patients are 
characterised by subtle alterations in thyroid parameters when compared to controls, and 3) to 
determine whether there is a continuous relationship between anxiety levels and thyroid parameters. 
Based on their symptom profiles and on the previous literature review by Simon et al. (2002), we 
mainly expected studies using patients with GAD, PD, and social anxiety disorder (SAD) to have 
investigated and revealed abnormalities in HPT functioning. 
 
Methods 
Search strategy 
Potentially relevant records were identified by systematically searching the PubMed and PsycINFO 
databases from 1990 until February 2017. Key words and subject headings were selected in 
accordance with the thesaurus of each database. The search string consisted of two components: 1) 
“anxiety disorder”, including synonyms and related terms and 2) “thyroid” and synonyms and related 
terms. Both searches were confined to studies conducted in humans. No language restrictions were 
applied, but one study was later excluded because it was written in Russian. 
 
Screening and study selection procedure 
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Three types of studies were to be included. The first type were “comorbidity studies” assessing the 
prevalence of thyroid disorders in individuals with anxiety disorders and/or their comorbidity in 
apparently healthy individuals of the general population. The second type were “case-control studies” 
comparing HPT parameters between patients with anxiety disorders and patients with other mental 
disorders or healthy controls. Anxiety disorders comprised all categories contained in the relevant 
DSM-5 chapter (APA, 2013) and applying to adults, namely specific phobia, SAD, PD, agoraphobia, 
and GAD, and had to be diagnosed according to DSM-III-R (APA, 1987), DSM-IV (APA, 2000), DSM-5 
(APA, 2013), or ICD-10 criteria (WHO, 1992). The third type were “correlational studies” assessing 
self-reported anxiety levels (using a validated questionnaire) and HPT parameters in patients with any 
of the above anxiety disorders or in apparently healthy individuals of the general population. Abiding 
by these inclusionary criteria meant that studies confined to specific populations (e.g., pregnant 
women) were excluded, and so were studies exclusively looking at patients with obsessive-compulsive 
disorder or posttraumatic stress disorder. Comorbidity with mental or somatic illnesses, however, was 
allowed, and so was the current intake of medication, but this was recorded. Full-text articles were 
retrieved and checked for relevant results. The reference sections of all articles were manually 
searched for additional records. 
 
Data extraction 
For each identified study, two members of the study team collected information about the authors, 
year of publication, the sample and setting, eligibility criteria, diagnostic procedures for the anxiety 
disorder, measurement of self-reported anxiety levels, diagnostic procedures for thyroid disorders, 
assessment of thyroid parameters, and the main study results. 
Risk of bias was assessed by means of a modified version of a quality rating scale that was first 
used in a meta-analysis on cortisol in functional somatic syndromes (Tak et al., 2011) and on cortisol 
in predicting treatment response in anxiety and depressive disorders (Fischer & Cleare, 2017; Fischer, 
Strawbridge, Vives, & Cleare, 2017). We adapted five of the original items (some were excluded due 
to non-applicability) to match the present research question and scored them using the original three-
point scale (0-2). The complete checklist can be found in Table 1. Depending on whether a control 
group was included in the study or not, the maximum attainable quality score was between 8 and 10. 
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- Insert Table 1 here - 
 
Results 
Search results 
The search yielded 1594 records, of which 38 were considered potentially relevant for the present 
research question based on their title or abstract. Of these, 18 studies were excluded due to the 
following reasons: they were not conducted in patients with a primary diagnosis of an anxiety disorder, 
did not diagnose anxiety disorders in accordance with DSM or ICD criteria, were single-case studies, 
did not assess thyroid functioning, or did not report relevant results. In total, 20 studies were eligible 
for data extraction. 
 
Study characteristics 
Tables 2-4 show the characteristics of all 20 included studies. Ten studies evaluated how frequently 
thyroid disorders were present in patients with anxiety disorders (comorbidity studies), nine compared 
thyroid parameters between patients with anxiety disorders and controls (case-control studies) and 
seven correlated self-reported anxiety levels with thyroid parameters (correlational studies). More 
detailed study characteristics are provided in the corresponding sections below. 
 
- Insert Tables 2-4 here - 
 
Risk of bias 
Depending on whether a control group was included in the study or not, the maximum attainable 
quality score was between 8 and 10. The average score was 3±1 (standard deviation; SD) for studies 
with a maximum score of 8 (range: 2-5) and 5±2 for studies with a maximum score of 10 (range: 3-8). 
This difference in means was mainly due to the fact that almost all of the latter studies scored points 
on the extra item for carefully selecting their control group. Across all studies, the highest scores were 
obtained for how hormonal assessments of the HPT axis were conducted, including the diagnostic 
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procedures for establishing thyroid disorders as well as the handling of samples to determine thyroid 
parameters (item 3). By contrast, only one study reported whether the assessors of anxiety were blind 
to thyroid status (item 4) and many studies failed to adjust their statistical analyses for relevant trait-
like confounders (item 5). More specifically, only two studies controlled for smoking, three for BMI and 
eight for depression. Age and sex, by contrast, were controlled for by the majority of studies. 
 
Comorbidity studies: thyroid disorders in patients with anxiety disorders 
Ten studies in total contained comorbidity analyses (see Table 2), using samples from the USA, South 
America, Europe, and Australia. Of these, four were conducted in community samples while the other 
six used outpatients. All four community studies found significant relationships between the presence 
of anxiety disorders and the presence of thyroid disorders, the latter established by questionnaires, 
medical interviews, physical examination, and/or laboratory testing. However, one of these studies 
later failed to replicate their positive finding in an independent sample of slightly older adults 
(Witthauer et al., 2016). All six outpatient studies mainly included patients with PD. The prevalence of 
any thyroid disorder in these patients ranged from 2.2% to 39.3%, with some studies relying on 
medical histories to obtain diagnoses and others measuring thyroid parameters and using cut-off 
values. Two of these studies compared patients with different types of anxiety disorders with each 
other. Both found that patients with GAD had the highest prevalence of comorbid thyroid disorders. 
Unfortunately, none of the comorbidity studies separated results into subclinical and overt forms of 
thyroid disorders. While most studies did not report which thyroid disorders they assessed, one study 
found hypothyroidism to be more common in PD (Gloger, Fardella, Santis, & Bitran, 1997), while 
another showed hyperthyroidism to prevail in the same patients (Fardella et al., 2000). 
 
Case-control studies: thyroid parameters in patients with anxiety disorders and controls 
Nine studies included case-control comparisons (see Table 3). These studies were conducted in the 
US, South America, and Europe. Most studies exclusively used outpatients with PD and all excluded 
patients with a history of thyroid disorders or any current somatic disease (including overt thyroid 
disorders). In terms of resting HPT parameters, none of the studies found any differences in 
cerebrospinal TRH, plasma/serum TSH, T3, free T4, or T4 when contrasting patients with healthy 
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controls. One study compared patients with PD to patients with depressive disorders and found that 
the former group had higher fT4 levels (Fardella et al., 2000). A more complex picture emerged when 
focusing on stimulated thyroid parameters, in this case TSH after a 400-500 µg TRH challenge. These 
challenges were conducted to test the integrity of the HPT axis, and most authors expected attenuated 
responses based on previous findings in depressed patients. Of the four studies, two indeed showed 
blunted responses in patients when compared to healthy controls, while the other two could not detect 
any differences (continuous analyses). When separating patients and controls into normal vs. 
abnormal responders (cut-off of 5 µU/ml or 7 µU/ml), again two out of the four studies found that 
patients more often fell into the abnormal responder category. Overall, three of the four studies 
reported some evidence for attenuated TSH responses in anxious patients, be it based on continuous 
or categorical analyses. 
 
Correlational studies: self-reported anxiety levels and thyroid parameters 
Seven studies correlated self-reported anxiety levels with thyroid parameters (see Table 4). These 
studies were conducted in the USA, Europe, and Japan. The settings included general population 
based samples, primary care samples, outpatient and inpatient samples. The one general population 
based sample split participants into those with vs. without current T4 intake and found a positive 
relationship between TSH and anxiety levels in medicated and a negative relationship in unmedicated 
individuals (Panicker et al., 2009). The latter finding was confirmed in a large primary care sample of 
older patients (Roberts et al., 2006), while an earlier study in a similar setting and using a small 
sample of younger females had failed to find such a link (Balada, Torrubia, & Arque, 1992). Two of the 
four clinical studies showed no dose-response relationship between resting or stimulated thyroid 
parameters and anxiety levels, while the other two showed a negative association between THR 
stimulated TSH, resting fT4 and anxiety levels in patients with PD. 
 
Discussion 
The aim of this systematic review was to investigate the extent to which patients with anxiety disorders 
are affected by thyroid dysfunction. We report three main findings: First, patients with an anxiety 
disorder were significantly more likely to concomitantly have a thyroid disorder. Second, patients with 
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PD and SAD did not differ from healthy controls in resting thyroid parameters, but half of the studies 
found evidence for attenuated TSH responses upon stimulation with TRH. Third, there was evidence 
for a negative relationship between self-reported anxiety and TSH levels. 
The first finding is in line with the first and only available review of the literature that was 
published 15 years ago (Simon et al., 2002), and extends it by providing evidence for comorbidity 
between anxiety and thyroid disorders in two different types of samples: population-based and clinical. 
This implies that the increased comorbidity cannot simply be attributed to selection bias, as may occur 
in treatment-seeking individuals, and thus increases the generalisability of this finding. Further adding 
to its robustness, the included studies greatly varied in how they assessed thyroid disorders, such as 
for example in their use of cut-off values for TSH, T3, T4, and/or antibodies, but still yielded conclusive 
results. This heterogeneity reflects ongoing controversies about the reference ranges for thyroid 
dysfunction and the general lack of consent in terms of diagnostic procedures (Chaker, Bianco, 
Jonklaas, & Peeters, 2017; De Leo et al., 2016). Notably, the nature (hypothyroidism vs. 
hyperthyroidism) and severity (subclinical vs. overt) of the comorbid thyroid disorders remains unclear, 
as barely any of the studies reported this. Moreover, there is a possibility that part of the observed 
comorbidity is due to the simultaneous presence of mood disorders, which were not always excluded 
or adjusted for. This is supported by the extremely high co-occurrence of GAD and mood disorders, 
which during the preparation of DSM-5 even led to suggestions of creating a category combining the 
two disorders (Goldberg et al., 2010). Finally, none of the studies was longitudinal, which means that 
the temporal order of this relationship could not be established. This is especially problematic seeing 
that cross-sectional research also shows that individuals with thyroid disorders have an increased 
probability of a concomitant anxiety disorder (e.g., Giynas Ayhan et al., 2014; Patten, Williams, 
Esposito, & Beck, 2006). However, in the study of Sareen et al. (2006) and Witthauer et al. (2016), 
using age-of-onset data, anxiety disorders were shown to precede the onset of thyroid disorders in the 
majority of cases, which could mean that subtle HPT axis alterations in anxious patients over time 
progress into subclinical and/or overt forms of thyroid disorders. 
Further support for this notion may be gained from studies comparing HPT axis functioning 
between anxious patients and healthy controls – both free of any overt thyroid conditions. According to 
the present review, there is no difference in any resting HPT axis parameter between the two groups. 
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This null-finding could either reflect real absence of subtle basal abnormalities in patients or be the 
due to methodological problems with single time point measurements, which are more susceptible to 
the influence of state-like confounders. For instance, thyroid parameters are known to follow specific 
circannual and circadian rhythms (Kim et al., 2013; Russell et al., 2008). Invariant sampling across 
seasons could thus have masked small group effects. By contrast, the fact that the null-finding was 
unanimous across studies with and without standardisation of sampling schedules renders it unlikely 
for time of day to have superimposed group effects. 
Results regarding stimulated TSH were equivocal, with half of the studies showing blunted 
responses to TRH challenge in anxious patients. All stimulation studies were remarkably 
homogeneous in the size of their sample and in their selection of patients: All used subjects in their 
mid-thirties, around half of which were women, and none of which had an overt thyroid disorder, were 
depressed, or currently using medication. There was more heterogeneity in terms of TRH 
administration and type of assay used, but none of these factors could explain the discrepant findings 
either. However, three out of four studies found some evidence for diminished TSH responses, either 
in continuous (peak TSH) or categorical (TRH non-responders vs. responders) analyses. One way to 
make sense of this is that an interaction of unreported patient characteristics (e.g., BMI) with specifics 
of the TRH test protocol (e.g., dosage) accounted for the observed inconsistencies. The finding of 
altered HPT functioning in PD and SAD aligns well with current knowledge about structural and 
functional thyroid-brain interactions. These include the presence of thyroid hormone receptors in 
various areas of the limbic system and cross-communication of the central thyroid, noradrenergic and 
serotonergic systems (Bauer et al., 2008). The molecular mechanisms underlying these connections 
and their potential role in contributing to anxiety-related symptoms merits further research, should the 
here reported evidence for subtle dynamic changes in the HPT axis be replicated. Notably, in those 
patients with (subclinical) hyperthyroidism, a diminished TSH response could suggest already existent 
stimulation of the pituitary by the hypothalamus, whereas in (subclinical) hypothyroidism, a diminished 
TSH response could suggest pituitary dysfunction. 
Finally, a negative association between self-reported anxiety levels and TSH emerged in two 
very large samples of the general population. This mirrors the first finding of significant comorbidity 
between anxiety disorders and thyroid disorders on a subclinical level. The results from patient 
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samples, however, were inconclusive and need to be interpreted with caution, since they were often 
reported as part of a secondary analysis and most studies failed to adjust these for relevant 
confounders (hence the low quality assessment scores). 
There are different explanations for what may reside at the core of the co-occurrence between 
anxiety and alterations in the HPT axis. It is possible that the observed comorbidity is a mere artefact. 
Heightened interoceptive sensitivity (Domschke, Stevens, Pfleiderer, & Gerlach, 2010) and intolerance 
of uncertainty (Carleton, 2012) are characteristic of many patients with anxiety disorders and may 
enhance the likelihood of being diagnosed with a thyroid disorder via increased healthcare seeking. 
This squares well with observations that individuals with subclinical forms of hyperthyroidism differ in 
the extent to which they experience and report symptoms (Cooper & Biondi, 2012). However, this 
hypothesis is refuted by the fact that those studies diagnosing thyroid disorders through physical 
examinations and laboratory testing rather than by reviewing medical histories still found their 
presence significantly linked with anxiety disorders (Carta et al., 2004; Sareen et al., 2006). Moreover, 
there was evidence for concomitant anxiety and HPT alterations on a subclinical level (case-control 
and correlational studies), again rendering this an unlikely scenario. Another explanation is common 
risk factors. Regular smoking and nicotine dependence is substantial in anxiety disorders (Morissette, 
Tull, Gulliver, Kamholz, & Zimering, 2007) and at the same time significantly increases the likelihood 
of developing overt hyperthyroidism, as present in Graves’ disease (Wiersinga, 2013). Against this, 
the two herein reviewed studies that controlled for smoking both still found the association between 
anxiety and thyroid dysfunction significant (Panicker et al., 2009; Sanna et al., 2013). Finally, there is 
the explanation of partly shared aetiopathogenetic mechanisms. Stress-related long-term alterations in 
the hypothalamic-pituitary-adrenal (HPA) axis are present in some patients with anxiety disorders 
(Elnazer & Baldwin, 2014) and may at the same time foster autoimmunity via shifting of the Th1/Th2 
immune balance (Elenkov, 2008; Montoro et al., 2009). This is in line with evidence for psychosocial 
stress preceding the onset of Graves’ disease, an autoimmune thyroid disorder (Bagnasco, Bossert, & 
Pesce, 2006). While the findings of the present review do not contradict this notion, they provide no 
direct support for it either. It is therefore upon future research to determine whether stress is indeed a 
contributor to the co-existence of anxiety and HPT abnormalities. 
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This is the first systematic review of the literature on HPT axis functioning in anxiety disorders. 
While we believe it useful in summarising the current state of research and outlining pitfalls and 
promises of future research, a number of limitations need to be considered. First, albeit 
comprehensive, our search yielded relatively few studies that matched the a priori defined eligibility 
criteria. This points out the need for further research in this somewhat neglected area. Second, there 
was substantial methodological heterogeneity. For instance, studies varied in their use of DSM-III-R 
versus DSM-IV criteria, which in terms of the present review means that the six epidemiological 
studies diagnosing GAD included slightly different patient populations. Heterogeneity was further 
increased by our decision to consider and combine evidence from different types of studies 
(comorbidity, case-control, and correlational). Considering this heterogeneity, we did not think it 
sensible to undertake a meta-analysis to determine the strength of the anxiety-thyroid dysfunction 
association. Third, while the HPT axis assessments were properly conducted in most studies, the risk 
of bias review also revealed a number of methodological limitations. For instance, despite excluding 
patients with a current major depressive episode, not all clinical studies assessed whether patients 
had a history of (hypo)manic episodes. Given the evidence for significant co-occurrence between PD 
and bipolar disorder (Vazquez, Baldessarini, & Tondo, 2014), and for HPT alterations in at least some 
patients with bipolar disorders (e.g., Barbuti et al., 2017; Kleiner et al., 1999), further case-control 
studies are advised to apply even more rigorous eligibility criteria. We also encourage future studies to 
systematically report the blinding of study personnel towards laboratory results and to rigorously 
control all statistical analyses for age, sex, BMI, smoking, and current levels of depression where 
applicable. 
Taken together, the present review found the comorbidity between anxiety disorders and 
thyroid disorders was significant. This is supportive of the recommendation to routinely screen for 
thyroid disorders when treating patients with anxiety disorders (e.g., Bandelow et al., 2014). Half of the 
studies supported the notion of subclinical thyroid dysfunction in that TSH responses to TRH 
administration were blunted and an inverse relationship was observed between self-reported anxiety 
levels and TSH. It is tempting to speculate that in some patients, anxiety and thyroid dysfunction partly 
emanate from shared aetiopathogenetic factors, such as stress. However, the risk of bias assessment 
of this review clearly underscores the need for more high-quality studies prior to further investigation of 
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this issue. Case-control designs including patients with different forms of anxiety and depression, and 
potentially other stress-related disorders presenting with bodily symptoms (e.g., somatic symptom 
disorder), seem particularly promising in this respect. Furthermore, the use of laboratory challenges 
mimicking real-life psychosocial stress (e.g., the Trier Social Stress Test; Kirschbaum, Pirke, & 
Hellhammer, 1993) may prove an intriguing alternative to pharmacologically probing the HPT axis with 
standardised doses of exogenous TRH. We further believe that longitudinal epidemiological research 
is necessary at this stage to delineate the temporal order in which anxiety and (subclinical) thyroid 
disorders evolve over the course of development. Combining these approaches should allow for 
further progress to be made in unravelling the extent and meaning of thyroid dysfunction in anxiety 
disorders. 
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Table legends 
Table 1 Quality rating scale to assess risk of bias in studies investigating the relationship between 
hypothalamic-pituitary-thyroid (HPT) functioning and anxiety (disorders); items modified from Tak et al. 
(2011), Fischer and Cleare (2017), and Fischer et al. (2017) 
Table 2 Characteristics of included studies assessing the prevalence of thyroid disorders in patients 
with anxiety disorders (comorbidity studies) 
Table 3 Characteristics of included studies measuring thyroid parameters in patients with anxiety 
disorders and controls (case-control studies) 
Table 4 Characteristics of included studies measuring anxiety levels and thyroid parameters 
(correlational studies) 
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Table 1 Quality rating scale to assess risk of bias in studies investigating the relationship between 
hypothalamic-pituitary-thyroid (HPT) functioning and anxiety (disorders); items modified from Tak et al. 
(2011), Fischer and Cleare (2017), and Fischer et al. (2017) 
1) What eligibility criteria were 
used? 
Non-clinical samples: 
Representative sample of the general population (2) 
Community or primary care sample (0) 
Clinical samples: 
Regulated iodine intake, no comorbidity with major somatic 
diseases, no comorbidity with major mental disorders, no 
current medication use, 3-4 used (2) 
Regulated iodine intake, no comorbidity with major somatic 
diseases, no comorbidity with major mental disorders, no 
current medication use, 1-2 used (1) 
Regulated iodine intake, no comorbidity with major somatic 
diseases, no comorbidity with major mental disorders, no 
current medication use, 0 used or not clearly stated (0) 
2) If applicable: How were controls 
recruited? 
From the same population as patients (2) 
From a selected population, such as hospital staff or students, 
or not clearly stated (0) 
3) How were thyroid disorders 
diagnosed or how were HPT 
measures taken? 
Thyroid disorders: 
Diagnosis based on established cut-off values (2) 
Medical history/interview (1) 
Self-reported diagnosis (0) 
HPT measures: 
HPT measure adequate regarding time of day, storage 
conditions, type of assay, intra- and inter-assay variance, 3-4 
fulfilled (2) 
HPT measure adequate regarding time of day, storage 
conditions, type of assay, intra- and inter-assay variance, 1-2 
fulfilled (1) 
HPT measure adequate regarding time of day, storage 
conditions, type of assay, intra- and inter-assay variance, 0 
fulfilled or not clearly stated (0) 
4) How was the blinding 
implemented regarding HPT 
measures? 
Assessor blind to case vs. control status or anxiety levels (2) 
Not blind or not clearly stated (0) 
5) What confounders were used to Age, sex, body mass index, smoking, depression, 4-5 stated (2) 
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adjust the statistical analyses?a Age, sex, body mass index, smoking, depression, 2-3 stated (1) 
Age, sex, body mass index, smoking, depression, 0-1 or not 
clearly stated (0) 
aIn case of the variable being an exclusionary criterion or in case of no significant impact on statistical 
analyses, consider confounder as adjusted for 
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Table 2 Characteristics of included studies assessing the prevalence of thyroid disorders in patients with anxiety disorders (comorbidity studies) 
Study Sample Anxiety disorder Thyroid disorder Main results Quality 
assessment 
Noyes et al. 
(1992) 
N=112 (73 female, 39 
male), mean age 
42±12, n=41 
generalised anxiety 
disorder, n=71 panic 
disorder 
Outpatient sample 
(USA) 
Inclusionary criteria: 
score > 18 on HRSA, 
≥1 panic attack in the 
past 4 weeks (patients 
with panic disorder 
only) 
Exclusionary criteria: 
panic attacks (patients 
with generalised 
anxiety disorder only), 
psychosis, organic 
mental disorder, 
primary mood disorder, 
serious physical illness 
Generalised anxiety 
disorder or panic 
disorder assessed by 
the SCID and HRSA 
Medical history of 
thyroid disease 
Prevalence of thyroid disorders in women 
with generalised anxiety disorder greater 
than in women with panic disorder 
5/10 
Rogers et al. 
(1994) 
N=711 (471 female, 
240 male), mean age 
41±13 
Current or past 
diagnosis of panic 
disorder, agoraphobia, 
generalised anxiety 
Medical history of 
thyroid disease 
Thyroid disease in 2% of male and 9% of 
female patients with panic disorder 
Prevalence of thyroid dysfunction only in 
3/10 
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Outpatient sample 
(USA) 
Inclusionary criteria: 
age >18 
Exclusionary criteria: 
organic mental 
syndrome, 
schizophrenia, current 
psychosis 
disorder, social phobia 
assessed by the SCID 
and SADS (results only 
available for panic 
disorder) 
females with panic disorder greater than in 
the general population (literature controls) 
Gloger et al. 
(1997) 
N=102 (74 female, 28 
male), mean age 
41±15, n=61 panic 
disorder (rest with 
depressive disorders) 
Outpatient sample 
(Chile) 
Exclusionary criteria: 
current medication use 
impacting on thyroid 
functioning 
Panic disorder 
assessed by a clinical 
interview 
TSH, T3, T4, fT4, TPO 
antibodies 
Hypothyroidism: TSH 
>10 μUl/ml; subclinical 
hypothyroidism: TSH 5-
10 μUl/ml 
Hyperthyroidism: T3 
>180 ng/dl and/or fT4 
>1.8 ng/dl with TSH 
<0.1 μUl/ml 
Positive for TPO 
antibodies: ≥1:100 
dilution 
Ultrasensitive 
chemiluminescence 
immunoassay and 
hemagglutination 
Thyroid disorder in 39.3% of patients with 
panic disorder: 19.7% hypothyroidism (n=2 
subclinical), 6.6% hyperthyroidism, 11.8% 
positive for TPO antibodies and/or goitre 
3/8 
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Chiovato et al. 
(1998) 
N=87, (70 female, 17 
male), mean age 36 
(range: 15-73) 
Outpatient sample 
(Italy) 
Exclusionary criteria: 
severe physical and 
laboratory 
abnormalities, current 
psychotic disorders, 
treatment with 
lithium/other drugs 
Panic disorder 
assessed by the SCID 
Family/personal history 
of thyroid disorders and 
physical examination 
No history of hyperthyroidism in patients with 
panic disorder (hypothyroidism not reported), 
but small diffuse goitres present in 18.3% 
2/8 
Fardella et al. 
(2000) 
N=268 (204 female, 64 
male), mean age 
38±14, n=28 panic 
disorder, n=28 panic 
disorder with major 
depressive disorder 
(rest with depressive 
disorder) 
Outpatient sample 
(Chile) 
Exclusionary criteria: 
major medical disease, 
comorbid axis I major 
psychiatric disorder, 
Panic disorder 
assessed by the SCID 
TSH, fT4, TPO 
antibodies 
Hypothyroidism: TSH > 
10μUl/ml; subclinical 
hypothyroidism: TSH 5-
10μUl/ml 
Hyperthyroidism: fT4 > 
1.4, TSH suppressed 
plus radioiodine uptake 
> 20% 
Positive for TPO 
antibodies: ≥1:100 
dilution 
No presence of hypothyroidism in patients 
with panic disorder only (only n=1 
subclinical), but 7.1% with hyperthyroidism 
and 21.4% were positive for TPO antibodies 
5/8 
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intake of lithium, 
carbamazepine, or oral 
contraceptives (past 6 
months) 
Automated 
chemiluminescence 
immunoassay and 
microhemagglutination 
Simon et al. 
(2002) 
N=169 (93 female, 76 
male), mean age 
37±10 
Outpatient sample 
(USA) 
Inclusionary criteria: 
age 18-65 
Exclusionary criteria: 
pregnancy, lactation, 
unstable medical 
illness, substance 
abuse, psychosis, 
bipolar disorder, OCD, 
PTSD, personality 
disorder, intake of 
psychotropic 
medication, history of 
hypersensitivity to 
study drug, ongoing 
psychotherapy for 
anxiety disorder 
Panic disorder, social 
phobia, generalised 
anxiety disorder 
assessed by the SCID 
or MINI 
Medical history of 
thyroid disease 
Serum TSH, T3, T4 
Hypothyroidism: TSH 
>10 mU/l plus abnormal 
T3 and/or T4 
Hyperthyroidism: 
undetectable TSH plus 
abnormal T3 and/or T4 
Sensitive assays 
Previously diagnosed or newly established 
thyroid disorder in 2.2% of patients with 
panic disorder, 4.2% of patients with social 
phobia, 10.4% of patients with generalised 
anxiety disorder 
Prevalence of thyroid dysfunction only in 
generalised anxiety disorder greater than in 
the general population (literature controls) 
4/10 
Carta et al. 
(2004) 
N=127 (79 female, 48 
male) 
Community sample 
Anxiety disorders 
assessed by simplified 
version of the CIDI 
Serum TSH, fT3, fT4, 
TPO antibodies 
Positive for TPO 
Only lifetime anxiety disorders not otherwise 
specified associated with being positive for 
TPO antibodies (other thyroid parameters 
3/8 
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(Sardinia) antibodies: ≥20 IU/ml 
Chemiluminescent 
assay, chromatographic 
method, 
radioimmunoassay, 
echography 
not reported) 
Sareen et al. 
(2006), see also 
Study I by 
Witthauer et al. 
(2016) 
N=4181 (2268 female, 
1913 male), age range 
18-65 
General population 
sample (Germany) 
Inclusionary criteria: 
age range 18-79 
Exclusionary criteria: 
hospitalised, not fluent 
in German 
Anxiety disorders 
assessed by the 
Munich CIDI 
Physical examination, 
laboratory testing 
Past-month anxiety disorder associated with 
increased likelihood of past-month thyroid 
disease 
4/8 
Sanna et al. 
(2013) 
N=942 (all male), mean 
age 59 (range: 46-73) 
Population-based 
sample (Australia) 
Inclusionary criteria: 
male, age 20-97 
Anxiety disorders 
assessed by the SCID 
Self-reported medical 
history, confirmed by 
medical records, 
medication use or 
clinical data where 
possible 
Lifetime anxiety disorder associated with 
increased likelihood of lifetime thyroid 
disease 
3/8 
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Witthauer et al. 
(2016), Study I 
see also Sareen 
et al. (2006) 
Two studies (original 
and replication study): 
Study I: N=4181 (2268 
female, 1913 male), 
age range 18-65 
General population 
sample (Germany) 
Inclusionary criteria: 
age range 18-79 
Exclusionary criteria: 
hospitalised, not fluent 
in German 
Study II: N=3691 (1961 
female, 1730 male), 
mean age 51 
Community sample 
(Switzerland) 
Inclusionary criteria: 
age 35-75, Caucasian 
Study I: specific phobia 
assessed by the 
Munich CIDI 
Study II: specific phobia 
assessed by the SADS 
Study I: self-reported 
questionnaire and 
medical interview by 
physician 
Study II: medical part of 
psychiatric interview 
Study I: Specific phobia in the past 12 
months associated with increased likelihood 
of lifetime thyroid disease 
Study II: Specific phobia in the past 12 
months not associated with increased 
likelihood of lifetime thyroid disease 
2/8 
CIDI = Composite International Diagnostic Interview 
MINI = Mini International Neuropsychiatric Interview 
OCD = obsessive-compulsive disorder 
HRSA = Hamilton Rating Scale for Anxiety 
HSCL = Hopkins Symptom Checklist 
PTSD = posttraumatic stress disorder 
SADS = Schedule for Affective-Disorders and Schizophrenia 
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SCID = Structured Clinical Interview for DSM-IV 
SCL-90 = Symptom Checklist-90 
T3 = triiodothyronine 
T4 = thyroxine 
TPO = thyroid peroxidase 
TSH = thyroid stimulating hormone 
Susanne Fischer 
31 
Table 3 Characteristics of included studies measuring thyroid parameters in patients with anxiety disorders and controls (case-control studies) 
Study Sample Anxiety disorder Thyroid measure Main results Quality 
assessment 
Tancer, Stein, 
Gelernter, and 
Uhde (1990) 
Three sub-studies with 
overlapping patients: 
Study I: N=52 (30 
female, 22 male), mean 
age 37±12, n=26 
patients, n=26 healthy 
controls 
Study II: N=35 (20 
female, 15 male), mean 
age 35±10, n=13 
patients, n=22 healthy 
controls 
Study III: N=86 (54 
female, 32 male), mean 
age 34±10, n=43 
patients, n=43 healthy 
controls 
Outpatient samples 
(USA) 
Exclusionary criteria: 
medical illness, history 
of thyroid disease, 
Social phobia 
assessed by the ADIS 
Study I: plasma TSH, 
T3, T4, fT4 
Study II: TRH (500 µg) 
challenge from 9-10 am: 
TSH measured at -15 
min, 0 min, +15 min, +30 
min, +45 min 
Study III: Tg antibodies, 
TPO antibodies at 4 pm 
Radioimmunoassay, 
equilibrium dialysis, 
indirect 
hemagglutination, 
tanned red cell method 
Study I: No differences in thyroid parameters 
between patients with social phobia and 
controls 
Study II: No differences in resting TSH 
between patients and controls, and no 
differences in responses in general, but 
patients more frequently showed blunted 
TSH responses when using a cut-off of either 
5 or 7 µlU/ml 
Study III: No differences in antibody titres 
between patients and controls 
6/10 
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major depression, 
intake of (thyroid) 
medication 
Stein, Muir-
Nash, and Uhde 
(1991) 
N=35 (19 female, 16 
male), mean age 32±6, 
n=15 patients, n=20 
healthy controls 
Psychiatric sample 
(USA) 
Exclusionary criteria: 
physical illnesses, 
medication use (past 2 
weeks) 
Panic disorder 
according to DSM-III-R 
criteria 
Plasma TSH, T3, T4, 
fT4 
No differences in thyroid parameters 
between patients with panic disorder and 
controls 
3/10 
Stein and Uhde 
(1991) 
N=48 (29 female, 19 
male), mean age 35±9, 
n=26 patients, n=22 
healthy controls 
Mixed outpatient (n=21) 
and inpatient (n=5) 
sample (USA) 
Exclusionary criteria: 
history of thyroid 
disease, physical 
illnesses, current major 
depression, medication 
Panic disorder 
assessed by the SADS 
TRH (500 µg) challenge 
at 9 am: TSH measured 
at 0 min, +15 min, +30 
min, +45 min, +60 min 
Immunoradiometric 
assay 
No differences in resting and stimulated TSH 
between patients with panic disorder and 
controls, and no differences regarding the 
frequency of blunted TSH responses when 
using a cut-off of 7μU/ml 
6/10 
Susanne Fischer 
33 
use (past 2 weeks) 
Fossey et al. 
(1993) 
N=56 (31 female, 25 
male), mean age 
35±10, n=45 patients, 
n=11 healthy controls 
USA 
Exclusionary criteria: 
major depression (only 
included when anxiety 
preceded onset of 
major depression), 
current axis I disorder, 
current medication use 
Panic disorder, 
generalised anxiety 
disorder, obsessive-
compulsive disorder 
assessed by the SCID 
Cerebrospinal TRH at 8-
10 am 
Radioimmunoassay 
No differences in TRH between patients with 
an anxiety disorder and controls 
4/10 
Chiovato et al. 
(1998) 
N=349, mean age 36 
(range: 15-73), n=87 
patients, n=262 healthy 
controls 
Outpatient sample 
(Italy) 
Exclusionary criteria: 
severe physical and 
laboratory 
abnormalities, current 
psychotic disorders, 
treatment with 
Panic disorder 
assessed by the SCID 
Serum TSH, fT3, fT4, Tg 
antibodies, TPO 
antibodies, TR 
antibodies 
Ultrasensitive 
immunoradiometric 
assay, 
radioimmunoassay 
No difference in the amount of detected 
antibodies between patients with panic 
disorder and controls (no other parameters 
reported) 
4/10 
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lithium/other drugs 
Tukel, Kora, 
Hekim, Oguz, 
and Alagol 
(1999) 
N=30 (14 female,16 
male), mean age 34±8, 
n=15 patients, n=15 
healthy controls 
Turkey 
Exclusionary criteria: 
past or current organic 
disorder, current major 
depressive episode, 
intake of medication 
(past 2 weeks) 
Panic disorder 
assessed by the SCID 
TRH (400 µg) challenge 
at 9 am: serum TSH 
measured at 0 min, +15 
min, +30 min, +60 min 
Chemiluminescent 
immunoassay 
No differences in resting TSH between 
patients with panic disorder and controls 
Blunted TSH response in patients when 
compared to controls 
Patients more frequently showed blunted 
TSH responses when using a cut-off of 5 
µlU/ml, but not when using a cut-off of 7 
µlU/ml 
6/10 
Fardella et al. 
(2000) 
N=268 (204 female, 64 
male), mean age 
38±14, n=28 panic 
disorder, n=28 panic 
disorder with major 
depressive disorder, 
n=168 major 
depressive disorder, 
n=44 bipolar disorder 
Outpatient sample 
(Chile) 
Exclusionary criteria: 
major medical disease, 
Panic disorder 
assessed by the SCID 
TSH, fT4, TPO 
antibodies 
Immunometric assay, 
chemiluminescence 
immunoassay, 
microhemagglutination 
Patients with panic disorder had higher fT4 
when compared to the other patient groups, 
while TSH did not differ across groups 
6/10 
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comorbid axis I major 
psychiatric disorder, 
intake of lithium, 
carbamazepine, or oral 
contraceptives (past 6 
months) 
Hofmann, 
Nutzinger, 
Kotter, and 
Herzog (2001) 
N=66 (33 female, 33 
male), mean age 
34±2.1, n=22 panic 
disorder, n=22 
agoraphobia without 
history of panic 
disorder, n=22 healthy 
controls 
Outpatient sample 
(Austria) 
Exclusionary criteria: 
medical disease 
(including thyroid 
disorders), medication 
intake (past week) 
Panic disorder or 
agoraphobia assessed 
by the SCID 
TRH (400 µg) challenge 
at 8 am: serum TSH 
measured at 0 min, +20 
min, +30 min, +40 min 
Radioimmunoassay 
(microparticle-enzyme-
immunoassay) 
Blunted TSH response in patients with panic 
disorder when compared to controls (resting 
TSH not reported) 
No difference between patients with 
agoraphobia and controls 
No differences across the three groups 
regarding the frequency of blunted TSH 
responses when using a cut-off of either 
5μU/ml or 7μU/ml 
8/10 
Kikuchi et al. 
(2005) 
N=66 (37 female, 29 
male), mean age 34 
(range: 16-75), n=46 
panic disorder with 
agoraphobia, n=20 
panic disorder without 
Panic disorder 
with/without 
agoraphobia according 
to DSM-IV criteria 
TSH, fT3, fT4 between 
10 am and 2 pm 
Enzyme immunoassay 
Medicated patients (probably 
antidepressants) with combined panic 
disorder and agoraphobia had higher fT3 
when compared to those with panic disorder 
only, while no differences emerged in 
unmedicated patients 
6/10 
Susanne Fischer 
36 
agoraphobia 
Outpatient sample 
(Japan) 
Exclusionary criteria: 
history of endocrine, 
cardiovascular, 
respiratory, hepatic or 
renal disease, TSH 
outside of normal 
range, history of other 
psychiatric disorders 
ADIS = Anxiety Disorder Interview Schedule 
DSM = Diagnostic and Statistical Manual of Mental Disorders 
FSS = Fear Survey Schedule-II 
SADS = Schedule for Affective Disorders and Schizophrenia 
SCID = Structured Clinical Interview for DSM 
STAI = State-Trait Anxiety Inventory 
T3 = triiodothyronine 
T4 = thyroxine 
Tg = thyroglobulin 
TPO = thyroid peroxidase 
TRH = thyroid releasing hormone 
TSH = thyroid stimulating hormone 
Susanne Fischer 
37 
Table 4 Characteristics of included studies measuring anxiety levels and thyroid parameters (correlational studies) 
Study Sample Anxiety measure Thyroid measure Main results Quality 
assessment 
Stein and Uhde 
(1991) 
N=48 (29 female, 19 
male), mean age 35±9, 
n=26 patients, n=22 
healthy controls 
Mixed outpatient 
(n=21) and inpatient 
(n=5) sample (USA) 
Exclusionary criteria: 
history of thyroid 
disease, current major 
depression, medication 
use (past 2 weeks) 
Panic disorder 
assessed by the 
SADS 
Anxiety (Sheehan 
Patient-Rated Anxiety 
Scale, STAI, ZAS) 
TRH (500 µg) challenge 
at 9 am: TSH measured 
at 0 min, +15 min, +30 
min, +45 min, +60 min 
Immunoradiometric assay 
No correlation between anxiety levels and 
TSH 
3/8 
Balada et. al 
(1992) 
N=37 (37 female), 
mean age 31 ± 6 
Family planning unit 
(Spain) 
Inclusionary criteria: 
normal menstrual cycle 
Exclusionary criteria: 
Anxiety (STAI) TSH, T3 and T4 between 
9.30 and 10.30 am 
Radioimmunoassay 
Anxiety levels not associated with thyroid 
parameters 
3/8 
Susanne Fischer 
38 
history of alcohol or 
drug abuse, endocrine 
or serious somatic 
illness, medication 
intake, oral 
contraceptive intake 
(past 6 months) 
Fossey et al. 
(1993) 
N=56 (31 female, 25 
male), mean age 
35±10, n=45 patients, 
n=11 healthy controls 
USA 
Exclusionary criteria: 
major depression (only 
included when anxiety 
preceded onset of 
major depression), 
current axis I disorder, 
current medication use 
Panic disorder, 
generalised anxiety 
disorder, or obsessive-
compulsive disorder 
assessed by the SCID 
Anxiety (Clinician-
Rated Anxiety Scale, 
HRSA, SCL-90) 
Cerebrospinal TRH at 8-
10 am 
Radioimmunoassay 
No association between any anxiety 
measure and TRH 
3/8 
Tukel et al. 
(1999) 
N=30 (14 female,16 
male), mean age 34±8, 
n=15 patients, n=15 
healthy controls 
Turkey 
Exclusionary criteria: 
past or current organic 
Panic disorder 
assessed by the SCID 
Anxiety (HRSA) 
TRH (400 µg) challenge 
at 9 am: serum TSH 
measured at 0 min, +15 
min, +30 min, +60 min 
Chemiluminescent 
immunoassay 
Anxiety levels negatively associated with 
TSH responses 
3/8 
Susanne Fischer 
39 
disorder, current major 
depressive episode, 
intake of medication 
(past 2 weeks) 
Kikuchi et al. 
(2005) 
N=66 (37 female, 29 
male), mean age 34 
(range: 16-75) 
Outpatient sample 
(Japan) 
Exclusionary criteria: 
history of endocrine, 
cardiovascular, 
respiratory, hepatic or 
renal disease, TSH 
outside of normal 
range, history of other 
psychiatric disorders 
Panic disorder 
with/without 
agoraphobia according 
to DSM-IV criteria  
Anxiety (STAI) 
TSH, fT3, fT4 between 10 
am and 2 pm 
Enzyme immunoassay 
Anxiety levels negatively associated with fT4 
in unmedicated patients (probably 
antidepressants), no significant correlation 
between hormone levels and anxiety level in 
medicated patients 
3/8 
Roberts et. al 
(2006) 
N=5868 (2985 female, 
2883 male), mean age 
73 ± 6 
Primary care sample 
(United Kingdom) 
Inclusionary criteria: 
age >65 years 
Exclusionary criteria: 
Depression and 
anxiety (HADS) 
Serum TSH, fT4, fT3 
(only when TSH or fT4 
abnormal) 
Chemiluminescent 
immunoassay 
Anxiety levels negatively associated with 
TSH, but not with fT4 
2/8 
Susanne Fischer 
40 
diagnosis of thyroid 
disease, current or past 
thyroid treatment (12 
months) 
Panicker et al. 
(2009) 
N=28’400 (18’959 
female, 9441 male), 
mean age 60±13 
General population 
sample (Norway) 
Inclusionary criteria: 
age >40 
Exclusionary criteria: 
use of psychotropic 
medication, history of 
thyroid but not on T4 
Anxiety (HADS) Blood TSH 
Ultrasensitive 
immunoradiometric assay 
Negative association between anxiety levels 
and TSH in subjects with no known thyroid 
disease 
In women on T4 anxiety positively 
associated with TSH (not enough power to 
test men) 
5/8 
BSI = Brief Symptom Inventory – anxiety subscale 
DSM = Diagnostic and Statistical Manual of Mental Disorders 
HADS = Hospital Anxiety and Depression Scale 
HRSA = Hamilton Rating Scale for Anxiety 
MINI = Mini International Neuropsychiatric Interview 
PHQ-9 = Patient Health Questionnaire – depression 
SADS = Schedule for Affective Disorders and Schizophrenia 
SCID = Structured Clinical Interview for DSM 
SCL-90 = Symptom Checklist 90 
STAI = State-Trait Anxiety Inventory 
T3 = triiodothyronine 
T4 = thyroxine 
TRH = thyroid releasing hormone 
TSH = thyroid stimulating hormone 
Susanne Fischer 
41 
ZAS = Zung Anxiety Scale 
